Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

Study Reaffirms Benefits of AlloMap, the Industry’s Only Gene-Expression Profiling Blood Test, for Heart Transplant Rejection Surveillance

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that AlloMap^®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,¹ resulted in less pain and fewer adverse events compared to heart biopsy.² The study also highlights that the associated AlloMap blood test draw can be performed in the patient’s home to help reduce the risk of exposure to infection. Read the complete press release on CareDx.com.